Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="236769"/>
  <meta>
    <versionId value="63"/>
    <lastUpdated value="2024-12-14T08:46:28.847Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 236769</b></p><a name="236769"> </a><a name="hc236769"> </a><a name="236769-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 63; Last updated: 2024-12-14 08:46:28+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-definition.html">ExposureDefinition</a></p></div><p><b>Artifact Author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: part-of; resourceReference: -&gt;display: string (PrimitiveType/Group.extension[1].value[x].resourceReference.display): element = string -&gt; display=string[MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes])</p><p><b>url</b>: <a href="https://fevir.net/resources/Group/236769">https://fevir.net/resources/Group/236769</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/236769, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-intervention-85394-I-85798</p><p><b>name</b>: Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798</p><p><b>title</b>: InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ExposureDefinition}">ExposureDefinition</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="part-of"/>
      <resourceReference>
        <type value="Composition"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
      </resourceReference>
    </valueRelatedArtifact>
  </extension>
  <url value="https://fevir.net/resources/Group/236769"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/236769"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="MAGIC-5288-j1Wqrn-intervention-85394-I-85798"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798"/>
  <title
         value="InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ExposureDefinition"/>
        <display value="ExposureDefinition"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
</Group>